College of Pharmaceutical Sciences, Zhejiang University, Hangzhou 310058, China.
State Key Laboratory of Chinese Medicine Modernization, Innovation Center of Yangtze River Delta, Zhejiang University, Jiaxing 314100, China.
ACS Chem Neurosci. 2024 Nov 20;15(22):4092-4094. doi: 10.1021/acschemneuro.4c00657. Epub 2024 Nov 2.
Parkinson's disease (PD) is one of the most prevalent neurodegenerative disorders, with current treatments offering only temporary symptomatic relief. There is an urgent need for the development of novel therapeutic approaches. Abnormal increases in LRRK2 kinase activity have been identified in both sporadic and familial PD patients, suggesting that inhibiting LRRK2 kinase activity presents a promising avenue for the pursuit of effective PD treatment strategies. In this Viewpoint, we discuss the exciting new insights regarding the development of LRRK2 kinase inhibitors as a treatment for Parkinson's disease.
帕金森病（PD）是最常见的神经退行性疾病之一，目前的治疗方法只能提供暂时的症状缓解。因此，迫切需要开发新的治疗方法。在散发性和家族性 PD 患者中，均发现 LRRK2 激酶活性异常增加，这表明抑制 LRRK2 激酶活性为探索有效的 PD 治疗策略提供了一个很有前途的途径。在本观点中，我们讨论了开发 LRRK2 激酶抑制剂作为治疗帕金森病的新的令人兴奋的见解。
